5 Pharma Stocks With Strong US Market Exposure: Can New Product Launches Drive Growth in FY27?
India, Nov. 21 -- The United States drug market continues to be a growth catalyst for Indian pharmaceutical companies, but growth is expected in complex generics, speciality drugs, biosimilars and unique formulations. However, pricing, regulatory pressures, and competition from generic companies will still be determining factors.
Q2 FY27 results have shown that various companies have been experiencing different trends. While some are growing their US revenues through new launches and acquisitions, other companies are trying to build up their revenue through specialty product lines and unique formulations.
Zydus Lifesciences
For Q2 FY27, Zydus Lifesciences witnessed consolidated revenue from operations at Rs. 7,910 crore, marking 29% YoY...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.